atomoxetine sold brand name strattera medication used treat attention deficit hyperactivity disorder lesser extent cognitive disengagement may used alone along also used cognitive executive functioning enhancer improve selfmotivation persistence attention inhibition working use atomoxetine recommended least six years taken atomoxetine selective norepinephrine reuptake inhibitor believed work increasing norepinephrine dopamine levels common side effects atomoxetine include abdominal pain loss appetite nausea feeling tired serious side effects may include angioedema liver problems stroke psychosis heart problems suicide lack data regarding safety pregnancy safety pregnancy use breastfeeding approved medical use united states commonly prescribed medication united states million atomoxetine indicated treatment attentiondeficithyperactivity disorder atomoxetine approved use children adolescents however efficacy studied children six years one primary differences standard stimulant treatments adhd little known abuse according studies metaanalyses response rate atomoxetine matches methylphenidate equally effective immediate release methylphenidate terms degree improvement reducing adhd symptoms although oros methylphenidate produces slightly superior benefit efficacy may less evidence may used combination doctors may prescribe nonstimulants including atomoxetine person bothersome side effects stimulants stimulant effective combination stimulant increase cost stimulants prohibitive concern abuse potential psychostimulants patient history drug use disorder unlike adrenoceptor agonists guanfacine clonidine atomoxetines use abruptly stopped without significant discontinuation effects initial therapeutic effects atomoxetine usually take weeks become weeks may required full therapeutic effects incrementally increasing response may occur year maximum recommended total daily dose children adolescents kg adults atomoxetine sometimes used treatment cognitive impairment frontal lobe symptoms due conditions like traumatic brain injury used goal treating symptoms like attentional problems lack arousal fatigue cochrane review identified one study atomoxetine tbi found positive aside tbi atomoxetine found effective treatment akinetic mutism following subarachnoid hemorrhage case contraindications common side effects include abdominal pain loss appetite nausea feeling tired serious side effects may include angioedema liver problems stroke psychosis heart problems suicide metaanalysis found atomoxetine associated anorexia weight loss hypertension rating potentially least preferred agent based safety treating safety pregnancy breastfeeding review stated lack data treating physician consider stopping atomoxetine treatment women adhd us food drug administration fda issued black box warning suicidal similar warnings issued unlike stimulant medications atomoxetine abuse liability potential cause withdrawal effects abrupt common incidence adverse effects common incidence adverse effects include uncommon incidence adverse effects include rare incidence adverse effects including atomoxetine relatively nontoxic overdose singledrug overdoses involving mg atomoxetine resulted common symptoms overdose less common recommended treatment atomoxetine overdose includes use activated charcoal prevent absorption atomoxetine substrate concurrent treatment inhibitor bupropion fluoxetine paroxetine shown increase plasma atomoxetine well increase ndesmethylatomoxetine levels decrease plasma levels similar atomoxetine found directly inhibit herg potassium currents μm potential cause qt prolongation reported atomoxetine therapeutic doses overdose suggested atomoxetine used medications may prolong qt interval concomitantly inhibitors caution used poor notable drug interactions atomoxetine inhibits presynaptic norepinephrine transporter net preventing reuptake norepinephrine throughout brain along inhibiting reuptake dopamine specific brain regions prefrontal cortex dopamine transporter dat expression rats atomoxetine increased prefrontal cortex catecholamine concentrations without altering dopamine levels striatum nucleus accumbens contrast methylphenidate dopamine reuptake inhibitor found increase prefrontal striatal accumbal dopamine levels addition rats atomoxetine also found induce similar regionspecific catecholamine level alteration atomoxetines status serotonin transporter sert inhibitor clinical doses humans uncertain pet imaging study rhesus monkeys found atomoxetine occupied neural net sert however mouse rat microdialysis studies failed find increase extracellular serotonin prefrontal cortex following acute chronic atomoxetine supporting atomoxetines selectivity human study found effects platelet serotonin uptake marker sert inhibition inhibition pressor effects tyramine marker net atomoxetine found act nmda receptor antagonist rat cortical neurons therapeutic causes usedependent openchannel block binding site overlaps binding atomoxetines ability increase prefrontal cortex firing rate anesthetized rats could blocked receptor antagonists could potentiated nmda receptor antagonist suggesting glutaminergic sprague dawley rats atomoxetine reduces protein content without altering transcript aberrant glutamate nmda receptor function implicated etiology atomoxetine also reversibly inhibits girk currents xenopus oocytes concentrationdependent voltageindependent timeindependent ion channels opened downstream stimulation well gicoupled therapeutic concentrations atomoxetine within range interacting girks especially poor known whether contributes therapeutic effects atomoxetine adhd major active metabolite atomoxetine extensive metabolizers found submicromolar affinity opioid receptors acting antagonist μopioid receptors partial agonist κopioid known whether action kappaopioid receptor leads cnsrelated adverse effects orally administered atomoxetine rapidly completely firstpass metabolism liver dependent activity resulting absolute bioavailability extensive metabolizers poor maximum plasma concentration reached taken food maximum plasma concentration decreases delays tmax drugs affecting gastric ph effect oral following intravenous delivery atomoxetine volume distribution lkg indicating distribution primarily total body water limited partitioning red blood highly bound plasma proteins mainly albumin along glycoprotein igg metabolite ndesmethylatomoxetine bound plasma proteins halflife atomoxetine varies widely individuals average range atomoxetine metabolized exposure may increased poor among extensive metabolizers halflife atomoxetine averaged hours halflife active metabolite ndesmethylatomoxetine contrast among poor metabolizers halflife atomoxetine averaged hours halflife ndesmethylatomoxetine averaged steadystate levels atomoxetine typically achieved around day regular dosing trough plasma concentrations ctrough residing around however time steadystate levels ctrough expected vary based patients atomoxetine ndesmethylatomoxetine produce minimal inhibition inhibit human liver microsomes concentrations μmollcitation needed plasma concentrations ndesmethylatomoxetine steady state atomoxetine extensive metabolizers atomoxetine poor atomoxetine excreted unchanged urine total dose excreted urine fractions excreted urine glucuronide account given dose extensive metabolizers poor poor metabolizers excrete greater amounts minor metabolites namely ndesmethylatomoxetine chinese adults homozygous hypoactive allele found exhibit twofold higher areaunderthecurve aucs higher maximum plasma concentrations compared extensive japanese men homozygous similarly found experience twofold higher aucs compared extensive atomoxetine white granular powder highly soluble water strattera capsule back strattera capsule front lilly logo atomoxetine may quantitated plasma serum whole blood order distinguish extensive versus poor metabolizers receiving drug therapeutically confirm diagnosis potential poisoning victims assist forensic investigation case fatal atomoxetine manufactured marketed sold united states hydrochloride salt atomoxetine hcl brand name strattera eli lilly company original patentfiling company current us patent owner atomoxetine initially intended developed antidepressant found insufficiently efficacious treating depression however found effective adhd approved fda treatment adhd patent expired may august lilly lost lawsuit challenged patent strattera increasing likelihood earlier entry generic us september sun pharmaceuticals announced would begin manufacturing generic united july conference call however sun pharmaceuticals chairman stated lilly litigation appeal think generic stratteras fda approved generic production atomoxetine four pharmaceutical drug originally known tomoxetine renamed avoid medication errors name may confused india atomoxetine sold brand names including axetra axepta attera tomoxetin attentin australia canada italy portugal romania spain switzerland us atomoxetine sold brand name strattera czech republic sold brand names including mylan iran atomoxetine sold brand names including stramox generic version approved united suggestion atomoxetine might helpful adjunct people major depression particularly cases concomitant atomoxetine may used adhd bipolar disorder although use well benefit also seen people adhd norepinephrine reuptake inhibitors appears reduce anxiety depression symptoms although attention focused mainly specific patient groups concurrent methamphetamine studies indicate atomoxetine effective treatment cognitive disengagement httpsenwikipediaorgwikiatomoxetine